The primary objectives in managing DM associated with acromegaly involve regulating levels of GH and IGF-I, minimizing tumor size, alleviating symptoms, addressing associated signs and comorbidities, and, ultimately, aiming to decrease mortality rates [22]. This evidence concerns the gene IGF1 and acromegaly.